Clinical Trials Using Acalabrutinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Acalabrutinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-19 of 19
  • A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma

    This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma.
    Location: 404 locations

  • Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    This screening and multi-sub-study Phase 1b / 2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
    Location: 17 locations

  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

    This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
    Location: 16 locations

  • Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

    Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R / R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R / R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R / R FL
    Location: 11 locations

  • Acalabrutinib, Venetoclax, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well acalabrutinib, venetoclax, and obinutuzumab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib, venetoclax, and obinutuzumab may work better in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 6 locations

  • Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

    The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
    Location: 6 locations

  • Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

    This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed / refractory aggressive Non-Hodgkin's Lymphoma (NHL).
    Location: 4 locations

  • Acalabrutinib with or without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 3 locations

  • A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

    This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when administered concomitantly with venetoclax and rituximab in subjects with treatment naive mantle cell lymphoma (Part 2).
    Location: 2 locations

  • Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

    This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib, lenalidomide, and rituximab may help to control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Rituximab and Acalabrutinib for the Treatment of Newly Diagnosed B Cell Post-Transplant Lymphoproliferative Disorder

    This phase II trial studies how well rituximab and acalabrutinib work in treating newly diagnosed B cell post-transplant lymphoproliferative disorder (PTLD) patients. Rituximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Acalabrutinib is an inhibitor of bruton tyrosine kinase (BTK). BTK is important in B cells and plays a role in the development of PTLD. The purpose of this trial is to evaluate how effective rituximab and acalabrutinib are when given as a combination treatment for PTLD.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

    This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
    Location: 4 locations

  • Acalabrutinib and Rituximab, Ifosfamide, Carboplatin and Etoposide for the Treatment of Patients with Relapsed / Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia / / Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma

    This phase II trial investigates the use of acalabrutinib and how well it works in combination with rituximab, ifosfamide, carboplatin and etoposide, in treating patients with non-germinal center diffuse large B cell lymphoma, transformed chronic lymphocytic leukemia / small lymphocytic leukemia or transformed marginal zone lymphoma that has come back (after a period of improvement) (relapsed) or does not respond to treatment (refractory). Acalabrutinib is a type of drug that blocks proteins inside cells that help cells live and grow. It is possible that acalabrutinib may kill the cancer cells or stop them from growing. The specific protein blocked by acalabrutinib is believed to help blood cancer cells live and grow. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body that can kill cancer cells. Ifosfamide, carboplatin and etoposide are types of a drug that causes deoxyribonucleic acid (DNA) damage, kills cancer cells and stops them from growing. Giving acalabrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide may improve durable responses in patients.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

  • Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

    This phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respond to treatment (refractory). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth cancer cells by blocking BCL-2 protein needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and venetoclax together with early obinutuzumab may improve clinical outcomes and control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

    Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: People ages 18 and older with an aggressive B-cell lymphomas that have not been treated Design: Participants will be screened with: Blood and urine tests Physical exam Medical history Tumor biopsy Bone marrow biopsy: A needle will remove marrow from the participant s hipbone. Lumbar puncture: If necessary, a needle will remove fluid from the participant s spinal canal. Imaging scans Participants will take the study drug for up to 14 days. It is a pill taken 2 times a day. Then they will have more scans. They will get rituximab and chemotherapy. They may get these drugs through a needle in an arm vein. Or they may them through a tube placed in a vein in their chest or in their neck. They might also keep taking the study drug. Each treatment cycle lasts 21 days. They will have up to 6 cycles. Participants may have 4 doses of another drug injected into their spinal fluid. Participants will have repeats of the screening tests throughout the study. Participants will have a follow-up visit 30 days after their last treatment, then every 3 months for 2 years, then every 6 months for 3 years, and then yearly. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Venetoclax and Acalabrutinib in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma

    This phase II trial studies the safety and efficacy of venetoclax and acalabrutinib combination in treating patients with mantle cell lymphoma that did not respond to previous treatment (refractory) or has come back (recurrent). Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination of venetoclax and acalabrutinib may help control mantle cell lymphoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

    CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Acalabrutinib and Anti-CD19 CAR T-cell therapy for the Treatment of B-cell Lymphoma

    This phase I / II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington